Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Actinium-225 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced or Metastatic Cancers

NCT05204147 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05204147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05204147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Actinium-225 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced or Metastatic Cancers
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
June 2, 2022
Completion date
September 10, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer